Quick Heal
Security Simplified

Quick Heal Technologies Ltd.

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor,
Opposite Neco Garden Society, Viman Nagar, Pune 411014.
Tel: +91 20 66813232 | Email: cs@quickheal.co.in
CIN - L72200MH1995PLC091408

Ref. No.: QHTL/Sec/SE/2021-22/13 May 17, 2021

The Manager,
Corporate Services,
BSE Limited,
14th floor, P J Towers, Dalal Street,
Mumbai – 400 001
Ref: Security ID: QUICKHEAL
Security Code: 539678

The Manager,
Corporate Services,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Symbol: QUICKHEAL
Series : EQ

Dear Sir/Madam,

Subject: Report of the Monitoring Agency for the quarter ended March 31, 2021

Please find enclosed herewith a Report of the Monitoring Agency, for the quarter ended March 31, 2021, for your records.

As permitted, this letter is being submitted under Sd/- mode due to work from home as per the Government advisory on Covid-19 and as a part of safety measure.

This is for your information and records.

Please acknowledge the receipt.

Quick Heal
Security Simplified

For Quick Heal Technologies Limited

Sd/-

A. Srinivasa Rao
Company Secretary

Encl.: As above

AXB/CO/IFB-TS/21-22/08
April 19, 2021

To,
Quick Heal Technologies Limited
Marvel Edge, 7010 C&D, 7th Floor,
Opp. NECO Garden Society
Pune – 411 014.

Kind Attn: Mr. Shankar Shinde

Dear Sir,

Sub.: Quick Heal Technologies Limited - Initial public offering of equity shares by the Company aggregating upto Rs. 250 Crores.

We write in our capacity of Monitoring Agent for the captioned initial public offering of the Company and refer to our duties cast under Regulation 41(2) of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2009.

In terms of above, please find attached the Monitoring Report for the quarter ended March 31st 2021 as per aforesaid SEBI Regulations.

Request you to kindly take the same on records.

Thanking you,
For **Axis Bank Limited**

Authorised Signatory

Report of the Monitoring Agency

Name of the Issuer: **Quick Heal Technologies Ltd**

For Quarter ended: **March, 2021**

Name of the Monitoring Agency: **Axis Bank Limited**

d(a) Deviation from the objects: **No deviation from the objects (relevant comments are specified in the report below)**

(b) Range of Deviation*: **Not applicable (relevant comments are specified in the report below)**

Declaration:

We hereby declare that this report is based on the format as prescribed by SEBI (ICDR) Regulations, 2009, as amended. We further declare that this report provides true and fair view of the utilization of issue proceeds.

We declare that we do not have any direct / indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship / interest while monitoring and reporting the utilization of issue proceeds by the issuer. We also declare that the certificate is provided on the basis of management representation and certification provided by the independent chartered accountant.

For Axis Bank Limited

Authorized Signatory
Date: 19 April, 2021

1) **Issuer Details:**

Name of the issuer: Quick Heal Technologies Ltd.
The names of the promoters of the issuer: Kailash Katkar, Sanjay Katkar, Anupama Katkar and Dr. Chhaya Katkar.
Industry/sector to which it belongs: Security software products and solutions.

2) **Issue Details**:

Issue Period: 16th February 2016 to 18th February, 2016
Type of issue (public/rights): Public Issue.
Type of specified securities: Equity Shares.
Grading: As this is an offer of Equity shares, no credit rating agency has been appointed in respect of obtaining grading for the offer.
Issue size (Rs. in Crores): Fresh issue of Rs. 250 crores

3) **Details of the arrangement made to ensure the monitoring of issue proceeds:**

(Give item by item description for all the objects stated in offer document separately in following format)

Particulars	**Comment**
Advertising and sales promotion	As per annexure attached 3.1
Capital expenditure on research and development	As per annexure attached 3.1
Purchase, development and renovation of office premises in Kolkata, Pune and New Delhi	As per annexure attached 3.1
General corporate purposes	As per annexure attached 3.1

Where material deviation may be defined to mean:
a) Deviation in the objects or purposes for which the funds have been raised
b) Deviation in the amount of fund actually utilized by more than 10% of the amount projected in the offer documents.

4) **Details of object(s)s to be monitored:**

(i) Cost of object(s)-

(Give Item by Item Description for all the Objects Stated in Offer Document separately in following format)
(Rs. in million)

Sl. No	Item Head	Original Cost (as per Offer Document)	Revised Cost	Comments of Monitoring Agency	Comments of Board of Directors		
					Reason of cost revision	Proposed financing option	Particulars of firm arrangements made
1.	Offer related expenses	157.49	174.74	The fact that estimated offer related expenses are short of actual expenses is mentioned in all earlier Utilization Certificate*			

* Relevant comments are provided in our report dated 25th October, 2016

(ii) Progress in the object(s)-Attached as Annexure 3.2

(iii) Deployment of unutilized IPO proceeds-

As all the funds related to offer has been utilized, there is no balance of unutilized funds available with the Company.

(iv) Delay in implementation of the object(s) -No. As per the objects of the offer stated in the prospectus the Total Net Proceeds received by Quick Heal Technologies Limited by way of IPO should be deployed during the fiscal years 2016,2017,2018 and 2019. However, if the funds are not utilized within prescribed period for reasons mentioned in prospectus, then such unutilized fund can be utilized in a fiscal year 2020 or any subsequent period as may be determined by the company.
Based on the above, the Board of Directors of Quick Heal Technologies Limited in meeting dated 13th February 2019 have decided to extend the utilization of Net Proceeds to the subsequent fiscal years upto 31 March 2021 stating that the same is within permissible reason as specified in prospectus.

ANNEXURE 3.1 TO THE MONITORING AGENCY CERTIFICATE DATED 15th April, 2021

Particulars	Reply	Monitoring Agency Comment	Comments of Board of Directors
Whether all the utilization is as per disclosure in Offer Document?	Yes	Utilization is as per disclosure in prospectus.	
Whether Shareholder approval is obtained in case of material deviations from expenditures disclosed in Offer Document?	Not Applicable	For the concerned period, there is no material deviation for the expenses incurred on advertising and sales promotion expenses and Capital expenditure on research development & General Corporate purpose	
Whether means of finance for disclosed objects of the Issue has changed?	No	Nil	
Any major deviation observed over the earlier monitoring agency reports?	No	Not to our knowledge	
Whether all Government / Statutory approvals related to the object(s) obtained?	Not Applicable	Nil	
Whether all arrangements pertaining to technical assistance/collaboration in operation?	Yes	Nil	
Any favorable events improving object(s) viability	No	Not to our knowledge	

Particulars	Reply	Monitoring Agency Comment	Comments of Board of Directors
Any unfavorable events affecting object(s) viability	No	Not to our knowledge	
Any other relevant information that may materially affect the decision making of the investors	No	Not to our knowledge	

ANNEXURE 3.2 TO THE MONITORING AGENCY CERTIFICATE DATED 15th April, 2021

Amount in million

Sl. No	Item Head	Amount as proposed in Letter of Offer	Amount utilized						Comments of Auditor	Comments of Board of Directors	
			As at Beginning of the quarter	During the quarter	At the end of the quarter	Transfer of funds after approval obtained in AGM dt. 15th July 2019	Transfer of funds after approval obtained in AGM dt. 11th August 2020	Total unutilized Amount		Reason of idle funds	Proposed Course of Action
1	Advertising and Sales Promotion	1110	736.89	123.11	860.00	0.00	-250.00	-	Expenses incurred on advertising and sales promotion are utilized from net proceeds and are in accordance with the objects of the offer as stated in prospectus. Amount of Rs. 250 is transferred from Advertising and Sales Promotion object to General Corporate Purpose object by resolution dated 11th August 2020		
2	Capital expenditure on research and development	418.80	418.80	-	418.80	0.00	0.00	-	Not Applicable.		
3	Purchase, development and renovation of office premises in Kolkata, Pune and New Delhi	275.95	188.72	-	188.72	-87.23	0.00	-	For the said quarter, there is no expenditure incurred on Purchase, development and renovation of office premises in Kolkata, Pune and New Delhi. Amount of Rs. 87.23 is transferred from Purchase, development and renovation of office premises in Kolkata, Pune and New Delhi object to General Corporate Purposes object by resolution dated 15th July 2019.		
4	General corporate purposes	537.76	617.38	257.61	874.99	87.23	250.00	-	Utilization is as per disclosure in prospectus. Amount of Rs. 87.23 is transferred from Purchase, development and renovation of office premises in Kolkata, Pune and New Delhi object to this object by resolution dated 15th July 2019. Amount of Rs. 250 is transferred from Advertising and Sales Promotion object to this object by resolution dated 11th August 2020. Further, Rs. 25,000 balance has been withdrawn as rounding off differences on 30 March 2021.		
	Total	**2342.51**	**1961.79**	**380.72**	**2342.51**	**-**	**-**	**-**			